#United States #Clinical Research #Exton #Frontage Laboratories #Teddy Lab

Frontage Laboratories Acquires Teddy Lab

Frontage Laboratories, Inc., a prominent player in the global Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) sectors, has made a significant move by acquiring Teddy Clinical Research Laboratory (Shanghai), Ltd. This acquisition marks a pivotal enhancement in Frontage's capabilities, particularly in Asia, positioning the company to better serve the increasing clinical research demands across the region.

Strengthening Regional Presence

The acquisition is not just a strategic business expansion; it represents Frontage’s commitment to bolstering its laboratory services on a global scale, especially in China. Teddy Lab is a well-established clinical research lab known for its compliance with Good Clinical Practice (GCP) and its contribution to more than 1,500 clinical trials in various therapeutic areas. With such a strong background, Teddy Lab is expected to bring invaluable expertise and operational efficiencies to Frontage's existing service offerings.

Enhancing Clinical Research Support

With the integration of Teddy Lab’s operations, Frontage can now offer an even more comprehensive service platform to its clients, which includes critical services such as bioanalytical testing, drug metabolism and pharmacokinetics (DMPK), safety and toxicology assessments, and clinical trial support. This enhancement aligns with current market trends, where there is a growing need for multi-regional clinical trials (MRCT) tapped from both domestic Chinese needs and international research demands.

Additionally, Teddy Lab’s laboratories are equipped with CAP accreditation and recognized as a Class II Unsealed Radioactive Material Workplace, which ensures that they meet global regulatory standards. The lab's contribution to the successful marketing of 50 new drugs signifies its pivotal role in the drug approval process, making the acquisition all the more strategic for Frontage.

Future Growth and Infrastructure Development

Frontage’s investment in expanding its global infrastructure is designed not only to support current demands but also to anticipate the evolving needs of the life sciences industry. The acquisition of Teddy Lab is a crucial step toward establishing a “one-stop shop” for high-quality drug development services, catering to pharmaceutical companies, biotech entities, contract research organizations, and research institutions worldwide.

As Frontage looks toward the future, this acquisition is expected to enhance its reputation as a trusted partner in clinical research and development. With over 25 years of experience in the industry and a commitment to quality, Frontage is well-positioned to leverage Teddy Lab's capabilities to meet the diverse needs of its clients.

Conclusion

In conclusion, Frontage Laboratories’ acquisition of Teddy Lab signals a strategic move to bolster its market presence in Asia and globally. As the demand for comprehensive laboratory services continues to rise, this integration helps ensure that Frontage remains at the forefront of the clinical research industry, delivering innovative solutions and supporting the development of new therapeutics that can improve patient outcomes around the world.

For more information about Frontage Laboratories and its services, please visit their website or contact their media relations team.

Media Contact: Xiaoyun Niu
Email: [email protected]
Phone: (610) 232-0100

Source: Frontage Laboratories, Inc.